We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical has announced the initiation of a large Phase III study designed to confirm the positive results from the Phase II study, which compared a new higher dose of 40 mg per day dose of glatiramer acetate (GA) to the currently approved Copaxone 20 mg for multiple sclerosis.
The Indo-U.S. Vaccine Action Program has announced it has decided to develop a revised road map based on priority diseases prevalent in both India and the U.S, including the development of candidate vaccines for rotaviral diarrhoea, malaria, HIV, tuberculosis, cholera, respiratory syncytial virus, Group A Streptococcus and more.
Pfizer has announced that Sutent (sunitinib malate) has received European Commission (EC) conditional marketing authorization for advanced or metastatic renal cell carcinoma, a type of advanced kidney cancer.
The introduction in India of a maximum retail price (MRP) inclusive of all taxes for drugs starting in October will create two pricing options for pharmaceutical companies throughout the country.
Ranbaxy Laboratories Ltd., which has been on a European buying spree, is also eyeing US acquisitions as it seeks to become one of the five largest generic manufacturers within six years.
Australian drug development company Alchemia Limited announced it had a relevant interest in Meditech Research Limited (Meditech) Ordinary Shares, representing 90.18 percent of Meditech's issued shares.
Shanghai Genomics Inc, the China-based affiliate of GNI and one of China's leading biotech companies, announced an agreement to collaborate on a drug discovery research project with Centocor, Inc. a U.S. based biopharmaceutical company and world leader in monoclonal antibody production and technology.
Generic medicines pharmaceutical company Genepharm Australasia Limited is set to launch its own generic brand of blockbuster drug Pravastatin (Pravachol) on August 1, the first PBS listing date for the generic drug after patent expiry in July 2006.
Dainippon Sumitomo Pharma (DSP) and Bristol-Myers K.K. (BMKK) have concluded an agreement on the marketing rights of anti-hypertension and hepatocellular cancer drug.